Nifty
Sensex
:
:
10600.05
35199.80
-56.15 (-0.53%)
-274.71 (-0.77%)

Pharmaceuticals & Drugs

Rating :
58/99

BSE: 524715 | NSE: SUNPHARMA

532.85
7.40 (1.41%)
21-Nov-2018 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  525.50
  •  536.30
  •  525.50
  •  525.45
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  4029454
  •  21470.95
  •  679.30
  •  435.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 126,084.70
  • 51.72
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 126,540.59
  • 0.38%
  • 3.07

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.38%
  • 4.10%
  • 6.72%
  • FII
  • DII
  • Others
  • 0.84%
  • 15.64%
  • 18.32%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.98
  • 10.44
  • -2.05

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.50
  • -4.48
  • -7.47

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 1.87
  • -6.99
  • -21.63

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 30.15
  • 40.83
  • 39.26

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.72
  • 5.82
  • 4.48

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.78
  • 19.15
  • 18.01

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Net Sales
6,937.63
6,650.34
4.32%
7,224.17
6,208.79
16.35%
6,977.10
7,136.96
-2.24%
6,653.23
7,925.11
-16.05%
Expenses
5,406.42
5,274.73
2.50%
5,617.47
5,113.14
9.86%
5,293.61
5,589.48
-5.29%
5,199.85
5,471.98
-4.97%
EBITDA
1,531.21
1,375.61
11.31%
1,606.70
1,095.65
46.64%
1,683.49
1,547.48
8.79%
1,453.38
2,453.13
-40.75%
EBIDTM
22.07%
20.68%
22.24%
17.65%
24.13%
21.68%
21.84%
30.95%
Other Income
351.15
254.84
37.79%
199.75
151.98
31.43%
302.75
224.50
34.86%
129.19
122.15
5.76%
Interest
129.53
157.44
-17.73%
130.90
109.42
19.63%
155.38
44.99
245.37%
95.33
166.47
-42.73%
Depreciation
426.51
358.65
18.92%
401.64
346.63
15.87%
455.24
338.17
34.62%
339.32
306.80
10.60%
PBT
111.94
1,114.36
-89.95%
1,273.91
-158.92
-
1,375.62
1,388.82
-0.95%
1,147.92
2,102.01
-45.39%
Tax
218.91
111.40
96.51%
163.86
161.78
1.29%
-176.69
44.30
-
748.70
372.92
100.77%
PAT
-106.97
1,002.96
-
1,110.05
-320.70
-
1,552.31
1,344.52
15.45%
399.22
1,729.09
-76.91%
PATM
-1.54%
15.08%
15.37%
-5.17%
22.25%
18.84%
6.00%
21.82%
EPS
-0.91
3.80
-
4.09
-1.77
-
5.46
5.10
7.06%
1.52
6.13
-75.20%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
27,792.13
26,415.54
31,308.14
28,108.61
27,392.01
16,080.36
11,299.86
8,019.49
5,727.90
4,007.45
4,272.30
Net Sales Growth
-0.46%
-15.63%
11.38%
2.62%
70.34%
42.31%
40.90%
40.01%
42.93%
-6.20%
 
Cost Of Goods Sold
7,734.32
7,318.73
8,164.20
6,170.19
6,732.84
2,777.68
2,076.36
1,647.61
1,460.40
1,098.45
848.40
Gross Profit
20,057.81
19,096.81
23,143.94
21,938.42
20,659.17
13,302.68
9,223.50
6,371.88
4,267.50
2,909.00
3,423.90
GP Margin
72.17%
72.29%
73.92%
78.05%
75.42%
82.73%
81.62%
79.45%
74.50%
72.59%
80.14%
Total Expenditure
21,517.35
20,880.73
21,625.92
19,950.29
19,615.54
9,120.95
6,437.76
4,836.43
3,785.07
2,644.63
2,408.35
Power & Fuel Cost
-
559.97
525.09
545.44
560.77
232.41
187.10
145.65
96.78
91.92
97.77
% Of Sales
-
2.12%
1.68%
1.94%
2.05%
1.45%
1.66%
1.82%
1.69%
2.29%
2.29%
Employee Cost
-
5,367.05
4,902.30
4,772.31
4,502.64
2,074.44
1,534.53
1,187.73
818.95
396.84
336.65
% Of Sales
-
20.32%
15.66%
16.98%
16.44%
12.90%
13.58%
14.81%
14.30%
9.90%
7.88%
Manufacturing Exp.
-
1,401.09
1,293.98
1,418.59
1,433.89
815.49
618.43
462.65
338.40
398.53
464.82
% Of Sales
-
5.30%
4.13%
5.05%
5.23%
5.07%
5.47%
5.77%
5.91%
9.94%
10.88%
General & Admin Exp.
-
3,288.76
3,113.67
2,956.85
2,894.97
978.48
793.38
629.48
480.66
215.47
144.49
% Of Sales
-
12.45%
9.95%
10.52%
10.57%
6.08%
7.02%
7.85%
8.39%
5.38%
3.38%
Selling & Distn. Exp.
-
1,864.55
2,520.64
2,262.35
2,236.40
1,394.78
763.01
516.55
372.14
290.33
388.60
% Of Sales
-
7.06%
8.05%
8.05%
8.16%
8.67%
6.75%
6.44%
6.50%
7.24%
9.10%
Miscellaneous Exp.
-
1,080.58
1,106.04
1,824.56
1,254.03
847.67
464.95
246.76
217.74
153.09
388.60
% Of Sales
-
4.09%
3.53%
6.49%
4.58%
5.27%
4.11%
3.08%
3.80%
3.82%
2.99%
EBITDA
6,274.78
5,534.81
9,682.22
8,158.32
7,776.47
6,959.41
4,862.10
3,183.06
1,942.83
1,362.82
1,863.95
EBITDA Margin
22.58%
20.95%
30.93%
29.02%
28.39%
43.28%
43.03%
39.69%
33.92%
34.01%
43.63%
Other Income
982.84
912.08
1,030.20
658.25
637.89
592.59
422.23
492.77
375.08
211.48
214.36
Interest
511.14
517.57
399.80
523.24
578.99
44.19
43.16
28.20
73.88
6.15
5.85
Depreciation
1,622.71
1,499.84
1,264.75
1,037.53
1,194.72
409.23
336.17
291.16
204.85
153.31
123.29
PBT
3,909.39
4,429.48
9,047.87
7,255.80
6,640.65
7,098.58
4,905.00
3,356.47
2,039.18
1,414.84
1,949.17
Tax
954.78
845.19
1,211.57
913.77
914.69
702.17
845.55
313.19
128.58
67.86
71.16
Tax Rate
24.42%
24.29%
13.39%
13.91%
14.29%
15.33%
19.57%
9.33%
6.31%
4.80%
3.65%
PAT
2,954.61
2,186.99
6,954.44
4,544.26
4,551.94
3,141.47
2,989.59
2,657.80
1,819.29
1,351.08
1,817.73
PAT before Minority Interest
2,461.27
2,633.79
7,836.30
5,656.86
5,488.21
3,879.00
3,475.87
3,043.28
1,910.60
1,346.98
1,878.01
Minority Interest
-493.34
-446.80
-881.86
-1,112.60
-936.27
-737.53
-486.28
-385.48
-91.31
4.10
-60.28
PAT Margin
10.63%
8.28%
22.21%
16.17%
16.62%
19.54%
26.46%
33.14%
31.76%
33.71%
42.55%
PAT Growth
-21.33%
-68.55%
53.04%
-0.17%
44.90%
5.08%
12.48%
46.09%
34.65%
-25.67%
 
Unadjusted EPS
10.16
9.00
29.00
18.90
18.90
15.20
14.40
25.70
17.50
13.00
87.80

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
38,100.56
36,639.67
32,982.48
25,638.09
18,524.95
14,989.73
12,235.78
9,483.32
7,828.91
7,044.92
Share Capital
239.93
239.93
240.66
207.12
207.12
103.56
103.56
103.56
103.56
103.56
Total Reserves
37,860.63
36,397.10
32,736.26
25,374.38
18,317.83
14,886.17
12,132.22
9,379.76
7,725.35
6,941.36
Non-Current Liabilities
259.98
599.87
2,169.59
2,335.46
1,748.41
199.02
-225.23
-188.27
82.11
110.99
Secured Loans
217.69
185.59
7.73
40.69
43.76
41.90
49.65
4.38
100.35
36.38
Unsecured Loans
1,554.40
1,250.49
3,102.57
1,327.73
4.91
73.36
105.77
152.90
70.80
142.51
Long Term Provisions
404.46
1,211.11
1,895.86
2,532.34
2,601.62
787.06
138.73
13.00
0.00
0.00
Current Liabilities
19,864.32
17,887.02
13,143.96
16,146.81
5,989.59
2,841.25
2,618.49
1,730.88
757.92
719.81
Trade Payables
4,766.20
4,395.39
3,582.92
3,286.54
1,328.26
1,057.99
992.72
645.38
319.44
254.34
Other Current Liabilities
1,875.93
2,673.68
1,134.27
2,279.59
260.41
218.65
363.66
362.42
90.07
122.37
Short Term Borrowings
7,979.70
6,654.92
5,206.12
6,227.92
2,440.34
82.95
109.57
207.78
0.00
0.00
Short Term Provisions
5,242.49
4,163.03
3,220.65
4,352.76
1,960.58
1,481.66
1,152.54
515.30
348.41
343.10
Total Liabilities
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49
11,873.08
8,862.13
8,072.76
Net Block
18,852.65
17,675.17
15,872.25
12,682.47
6,817.28
5,647.47
3,951.35
3,293.35
1,938.82
1,787.88
Gross Block
26,948.81
24,466.42
22,180.41
20,406.89
10,485.12
8,709.22
6,448.66
5,319.27
2,740.07
2,472.95
Accumulated Depreciation
8,096.16
6,791.25
6,308.16
7,724.42
3,667.84
3,061.75
2,497.31
2,025.92
801.25
685.07
Non Current Assets
30,473.12
25,963.77
22,439.98
18,055.80
9,497.56
8,161.89
5,496.96
4,279.84
3,567.95
3,004.28
Capital Work in Progress
2,465.16
2,801.38
2,175.45
2,038.61
841.54
562.61
344.65
235.46
144.82
157.10
Non Current Investment
3,052.25
961.00
1,116.07
598.87
787.56
1,106.35
588.96
346.01
1,484.31
1,059.30
Long Term Loans & Adv.
6,052.97
3,844.04
2,322.87
2,631.91
1,016.98
802.56
593.29
377.27
0.00
0.00
Other Non Current Assets
50.09
682.18
953.34
103.94
34.20
42.90
18.71
27.75
0.00
0.00
Current Assets
31,635.90
32,953.65
29,941.30
28,915.75
18,686.46
11,503.03
10,293.37
7,593.05
5,294.18
5,068.48
Current Investments
4,090.62
230.88
713.81
2,117.43
1,998.46
1,305.22
1,623.91
1,883.75
1,682.07
800.19
Inventories
6,880.69
6,832.81
6,422.54
5,667.99
3,123.01
2,577.76
2,086.98
1,489.48
1,073.85
975.70
Sundry Debtors
7,815.28
7,202.61
6,775.66
5,106.13
2,200.42
2,412.23
2,078.74
1,104.87
1,174.77
881.09
Cash & Bank
9,929.38
15,140.84
13,181.65
10,998.04
7,590.15
4,058.71
3,367.19
2,204.63
508.89
1,669.03
Other Current Assets
2,919.93
718.25
530.51
3,105.64
3,774.42
1,149.11
1,136.55
910.32
854.60
742.47
Short Term Loans & Adv.
2,028.62
2,828.26
2,317.13
1,920.52
1,093.74
952.93
976.71
784.37
835.09
685.21
Net Current Assets
11,771.58
15,066.63
16,797.34
12,768.94
12,696.87
8,661.78
7,674.88
5,862.17
4,536.26
4,348.67
Total Assets
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49
11,873.08
8,862.13
8,072.76

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
3,907.15
7,082.21
6,685.86
5,615.74
3,959.20
3,356.58
2,234.46
2,283.10
781.13
2,164.89
PBT
3,478.98
9,047.87
6,570.63
6,402.90
4,581.17
4,314.89
3,355.36
2,035.95
1,414.84
1,949.17
Adjustment
1,382.22
500.67
1,856.92
773.61
-40.15
160.00
111.12
-171.18
-23.60
381.77
Changes in Working Capital
-212.31
-409.21
246.77
179.59
207.10
-44.83
-1,005.25
487.65
-435.63
2.94
Cash after chg. in Working capital
4,648.89
9,139.33
8,674.32
7,356.10
4,748.12
4,430.06
2,461.23
2,352.42
955.61
2,333.88
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-741.74
-2,057.12
-1,988.46
-1,740.36
-788.92
-1,073.48
-226.77
-69.32
-174.48
-168.99
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-3,370.81
-4,221.60
-4,371.59
-2,865.74
-2,366.76
-2,635.05
-862.71
-1,847.71
-213.74
-1,773.02
Net Fixed Assets
-714.76
-1,217.15
2,214.23
-4,631.67
-380.81
-341.28
-267.49
-212.50
-114.06
-169.39
Net Investments
978.04
3,038.39
3,504.47
-18,860.43
-2,698.19
120.24
-836.36
450.27
-1,357.10
-751.47
Others
-3,634.09
-6,042.84
-10,090.29
20,626.36
712.24
-2,414.01
241.14
-2,085.48
1,257.42
-852.16
Cash from Financing Activity
-1,539.26
-2,285.39
-1,888.53
-1,186.53
506.57
-664.99
-544.39
-804.19
-346.43
-266.62
Net Cash Inflow / Outflow
-1,002.92
575.22
425.74
1,563.47
2,099.01
56.54
827.36
-368.80
220.96
125.25
Opening Cash & Equivalents
8,642.36
8,031.69
7,183.49
4,358.70
2,069.11
1,752.67
810.49
633.87
451.24
325.99
Closing Cash & Equivalent
7,906.45
8,642.36
8,031.69
7,285.56
4,358.70
2,069.11
1,752.67
810.49
672.20
451.24

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
158.80
152.70
137.03
123.49
89.44
72.37
59.08
45.79
37.80
34.01
ROA
4.35%
14.08%
11.39%
14.60%
16.21%
19.61%
22.00%
18.43%
15.91%
26.75%
ROE
7.05%
22.51%
19.32%
24.89%
23.15%
25.53%
28.02%
22.07%
18.11%
31.21%
ROCE
8.42%
21.48%
18.64%
25.06%
25.46%
31.39%
30.13%
23.60%
18.67%
31.64%
Fixed Asset Turnover
1.03
1.35
1.34
1.79
1.70
1.51
1.38
1.44
1.57
2.06
Receivable days
103.47
80.78
76.12
48.20
51.72
71.46
71.49
71.57
91.85
95.89
Inventory Days
94.48
76.61
77.46
57.99
63.92
74.22
80.31
80.48
91.57
72.94
Payable days
92.31
77.57
75.24
52.05
56.33
65.15
64.51
51.06
42.23
38.20
Cash Conversion Cycle
105.64
79.82
78.34
54.14
59.31
80.53
87.29
100.98
141.19
130.62
Total Debt/Equity
0.27
0.27
0.26
0.35
0.14
0.02
0.03
0.04
0.02
0.03
Interest Cover
7.72
23.63
13.56
12.06
104.67
101.13
120.02
28.60
231.06
334.19

News Update:


  • Sun Pharma reports consolidated net loss of Rs 219 crore in Q2
    14th Nov 2018, 10:26 AM

    Total consolidated income of the company increased by 5.56% at Rs 7,288.78 crore for Q2FY19

    Read More
  • Sun Pharma Inds. - Quarterly Results
    13th Nov 2018, 15:45 PM

    Read More
  • Sun Pharma comes up with psoriasis treatment drug ‘ILUMYA’ in US
    24th Oct 2018, 09:40 AM

    ILUMYA injections are administered by a healthcare provider every 12 weeks

    Read More
  • Sun Pharmaceutical to invest additional Rs 200 crore in Assam plant
    15th Oct 2018, 12:09 PM

    The company has inaugurated a new production line at its facility in Palashbari

    Read More
  • Sun pharma expects to stabilize India business in FY19
    4th Oct 2018, 10:43 AM

    Favorable demographics conditions will help the company to ensure reasonable volume growth in India

    Read More
  • Sun Pharma looking to raise share of complex generics, speciality products
    28th Sep 2018, 11:16 AM

    This should help the company to drive a stable and consistent growth in cash flows

    Read More
  • Sun Pharma receives Australian TGA approval for ILUMYA
    21st Sep 2018, 11:46 AM

    ILUMYA selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL23 receptor leading to inhibition of the release of proinflammatory cytokines and chemokines

    Read More
  • Sun Pharma’s Almirall gets EC approval for ILUMETRI
    19th Sep 2018, 09:36 AM

    The ILUMETRI is for the treatment of adults with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy

    Read More
  • Sun Pharma, SPARC get approval from USFDA for NDA of XELPROS
    14th Sep 2018, 08:55 AM

    The company in-licensed XELPROS from SPARC in June 2015 and this approval will trigger a milestone payment to SPARC

    Read More
  • USFDA conducting inspection at Sun Pharma’s Mohali facility
    12th Sep 2018, 09:39 AM

    The inspection by the USFDA started on September 10, 2018 and is ongoing

    Read More
  • Sun Pharma’s arm to acquire shares of Tarsius Pharma
    10th Sep 2018, 16:08 PM

    The cost of acquisition is $3 million

    Read More
  • USFDA completes inspection at Sun Pharma’s Halol plant in Gujarat
    8th Sep 2018, 09:04 AM

    After the inspection, USFDA has issued six observations

    Read More
  • Sun Pharma launches Volini Maxx
    29th Aug 2018, 14:21 PM

    The company has signed Virat Kohli as the new brand ambassador of Volini

    Read More
  • USFDA conducting inspection at Sun Pharma’s Halol facility: Report
    27th Aug 2018, 12:41 PM

    The site produces multiple dosage forms from tablets to ointments to injectable

    Read More
  • Sun Pharma gets approval from USFDA for CEQUA
    16th Aug 2018, 08:46 AM

    The innovative nanomicellar formulation allows the CsA molecule to overcome solubility challenges

    Read More
  • Sun Pharma turns black in Q1FY19
    14th Aug 2018, 15:27 PM

    Total consolidated income of the company increased by 16.71% at Rs 7,423.92 crore for Q1FY19

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.